Table 2. Correlation between methylation status and clinical parameters for the total group yrs (years), FD (first diagnosis), RD (recurrent disease), CTX (chemotherapy).

Characteristics total cohort n=124	Methylated n=66	%	Unmethylated n=58	%	p value
Age (yrs) at FD
Median (range)	63 (34-81)	n.a.	58 (31-75)	n.a.	0.029
Age (yrs) at RD
Median (range)	65 (38-81)	n.a.	61 (31-77)	n.a.
Lymph node status at FD
pN0	18	27.3	15	25.9	0.525
pN1	38	57.6	24	41.4
Nx	10	15.2	19	32.6
FIGO stage at FD
IA	0	0	1	1.7	0.476
IIIA/IIIB	8	12.1	4	6.9
IIIC	41	62.1	39	67.2
IV	16	24.2	11	19.0
unknown	1	1.5	3	5.2
Grading
High grade	66	100	58	100	0.584
Distant metastasis
M0	48	72.7	44	75.9	0.397
M1	16	24.2	10	17.2
unknown	2	3.0	4	6.9
Histology
Serous	54	81.8	51	88	0.733
Others	12	18.2	7	12.1
Undifferentiated	4		2
Clear cell	4		1
Mixed	2		1
Endometrioid	1		1
Mucinous	1		2
Neoadjuvant CTX at FD
No	54	81.9	49	84.5	0.263
yes	12	18.2	6	10.3
unknown	0	0	3	5.2
Residual tumour (FD)
microscopic	38	57.6	38	65.5	0.279
<1cm	17	25.8	8	13.8
>1cm	7	10.6	7	12.1
unknown	4	6.1	5	8.6